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Clinical trials of systemic therapy for operable 
breast cancer are evolving. Our understanding of 
breast cancer as a family of biologically distinct 
diseases has implications for patient selection and 
the optimization of drug choices. In addition, there 
is a growing dissatisfaction with trials of adjuvant 
therapy that are large, take many years to com-
plete, and often result in very small improvements 
in outcome. For these reasons, we must be 
thoughtful and rigorous in focusing the testing 
of promising agents in patients who could derive 
a meaningful benefit. These realities are in part 
responsible for the explosion of “neoadjuvant,” 
or preoperative, trials of systemic therapy in breast 
cancer. Neoadjuvant therapy, by virtue of the in-
termediate end point of complete tumor eradica-
tion before surgery (called pathological complete 
response), allows new regimens to be tested in 
much smaller trials and for results to be obtained 
far more rapidly than in adjuvant studies.
In this issue of the Journal, the Investigation of 
Serial Studies to Predict Your Therapeutic Re-
sponse through Imaging and Molecular Analysis 
2 (I-SPY 2 TRIAL) investigators report results from 
the first two trials of targeted agents added to 
chemotherapy.1,2 These trials use a new approach 
to trial design; rather than creating a fixed frame-
work of statistical assumptions that determines 
sample size and power, the trials react to results 
as they arrive. This adaptive approach potentially 
allows for faster and more flexible trial design.
Park and colleagues compared the use of a tra-
ditional chemotherapy backbone with either the 
small molecule neratinib or the standard mono-
clonal antibody trastuzumab. The pathological 
complete response rate was 56% versus 33% in 
favor of the neratinib regimen among patients 
with human epidermal growth factor receptor 2 
(HER2)–positive and hormone-receptor [estrogen 
receptor and progesterone receptor]–negative dis-
ease, and the results strongly suggest that a con-
firmatory neoadjuvant trial would have a high 
likelihood of showing neratinib to be the more 
effective agent (if an end point of pathological 
complete response were used). The second trial 
tested the same chemotherapy backbone with or 
without the poly(ADP-ribose) polymerase (PARP) 
inhibitor veliparib, administered with carboplat-
in. In patients with triple-negative (i.e., hormone-
receptor–negative and HER2-negative) breast can-
cer, the veliparib–carboplatin regimen yielded an 
estimated pathological complete response rate of 
51%, as compared with 26% for conventional 
chemotherapy alone, which again suggested that 
a confirmatory trial involving patients with triple-
negative disease would have positive results. On 
the basis of the Bayesian probability assumptions 
used in the trial, both of these approaches — 
neratinib in HER2-positive disease and veliparib–
carboplatin in triple-negative disease — “gradu-
ated” to the next phase of investigation.
Although these findings are encouraging, it 
is important to consider them in clinical context. 
Neratinib has shown early evidence of effective-
ness in the context of adjuvant therapy when it is 
administered after trastuzumab, but it causes 
clinically significant diarrhea in more than one 
third of patients, resulting in a high rate of early 
discontinuation.3 The phase 3 confirmatory study 
that the I-SPY 2 investigators propose compares 
two anti-HER2 agents (trastuzumab and pertu-
zumab) versus three agents (trastuzumab, pertu-
zumab, and neratinib). It is difficult to know 
whether predictions of success based on a single-
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agent trial can be extrapolated when multiple 
agents are combined. It is also possible, if not 
probable, that the three-drug regimen proposed 
would have considerable toxic effects when added 
to chemotherapy. This approach raises concerns 
and could result in substantial overtreatment of a 
large proportion of the patient population. In tri-
ple-negative disease, recent studies have consis-
tently found a higher pathological complete re-
sponse rate with the addition of platinum drugs4,5; 
given that the investigational regimen in the study 
by Rugo et al. included the addition of both a PARP 
inhibitor and a platinum drug, it is possible that 
the results were driven partially or entirely by the 
inclusion of the additional cytotoxic drug rather 
than by the targeted agent.
The potential for unmeasured variables to in-
fluence the results must be considered. We have 
learned that many nontreatment factors contrib-
ute to response to therapy in both HER2-positive 
and triple-negative breast cancer, such as intrinsic 
subtype and the presence or activity of tumor-
infiltrating lymphocytes.6-8 These may be particu-
larly relevant in small studies in which baseline 
imbalances can produce outsize effects. For these 
reasons, although the results of these studies are 
intriguing, the main benefit of the I-SPY 2 ap-
proach is in quickly providing data that can help 
investigators choose which of several promising 
new approaches to pursue in larger trials.
These two multicenter trials may ultimately 
lead to changes in treatment in the years ahead. 
The investigators created a collaborative culture 
around these studies, and the work that appears 
in the Journal would not have been possible absent 
that spirit of cooperation and collective creativity. 
However, these trials were not designed to predict 
the ultimate success of either neratinib or carbo-
platin–veliparib in improving disease-free or over-
all survival. Instead, they predict a positive result 
with the use of pathological complete response 
rate as an end point in a definitive neoadjuvant 
study. Clinicians should remember that pathologi-
cal complete response rate itself is not a clinically 
meaningful end point; its value is as a surrogate 
for outcome. Although pathological complete re-
sponse rate is consistently associated with a de-
creased risk of relapse and death for individual 
patients,9 even substantial improvements in path-
ological complete response rate in neoadjuvant 
trials have not consistently translated into improve-
ment in long-term outcomes. The reasons for this 
are myriad, including the molecular heterogeneity 
of breast cancer and the possible effect of post-
surgical interventions. Most importantly, patho-
logical complete response rate will correlate with 
survival outcomes only if the neoadjuvant agents 
leading to the improvement in pathological com-
plete response also eradicate resistant tumor 
clones. At this time, improvements in pathologi-
cal complete response rates as reported in neo-
adjuvant studies — whether the studies are ex-
ploratory, such as I-SPY 2, or more definitive 
— should not change clinical practice; rather, 
we should wait for the definitive clinical trials that 
result from them. Nonetheless, standard neoadju-
vant therapy remains a sound clinical approach 
with the potential to individualize therapy. It also 
remains a valuable research tool that has the po-
tential to help us develop hypotheses and explore 
mechanisms of drug resistance.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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